Back to MW MARSHALL WACE, LLP

EGRXEGRX
15 quarters

Position history for MWMARSHALL WACE, LLP's holdings in EAGLE PHARMACEUTICALS INC

No. Marshall Wace exited its EGRX (Eagle Pharmaceuticals) position in Q4 2024. Its Q3 2024 13F listed 223,353 shares worth $833,107. Marshall Wace already held EGRX in its Q4 2018 13F, the earliest on record, and held it in 11 quarterly 13F filings.

Final Value

$0

Final Shares

0

Total Value Change

-$4.5M

Total Shares Change

-111,464

Quarter-by-Quarter History
QuarterActionSharesChangeValueWeightPriceConviction
2024-Q4
Latest
Exited
0
-100.0%
$00.0%$0.50
0
2024-Q3
Increased
223,353
+14.3%
$833,1070.0%$3.95
28
2024-Q2
Decreased
195,475
-24.1%
$1.1M0.0%$5.60
0
2024-Q1
Increased
257,469
+79.0%
$1.3M0.0%$5.24
39
2023-Q4
New
143,826
-
$752,2100.0%$5.23
34
2023-Q2
Exited
0
-100.0%
$00.0%$19.47
0
2023-Q1
Increased
65,967
+331.8%
$1.9M0.0%$27.88
42
2022-Q4
New
15,276
-
$446,5170.0%$29.23
33
2021-Q2
Exited
0
-100.0%
$00.0%$42.14
0
2021-Q1
New
23,449
-
$979,0000.0%$41.06
35
2019-Q4
Exited
0
-100.0%
$00.0%$59.89
0
2019-Q3
Increased
51,590
+45.1%
$2.9M0.0%$56.43
36
2019-Q2
Decreased
35,550
-29.2%
$2M0.0%$55.68
0
2019-Q1
Decreased
50,188
-55.0%
$2.5M0.0%$50.49
0
2018-Q4
First report
111,464
-
$4.5M0.0%$39.23
0

Other major holders of EGRX: Janus Henderson Group Ltd.

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used